home / stock / immp / immp news

IMMP News and Press, Immutep Limited From 03/18/22

Stock Information
Company Name: Immutep Limited
Stock Symbol: IMMP
Market: NASDAQ
Website: immutep.com
Menu
IMMP IMMP Quote IMMP Short IMMP News IMMP Articles IMMP Message Board
Get IMMP Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMP - Immutep announces Japan granted second patent for cancer therapy

Clinical-stage biotech, Immutep Limited (NASDAQ:IMMP) announced on Friday that the Japanese Patent Office issued a second patent related to its experimental cancer therapy LAG525 co-developed by Swiss pharma giant Novartis (NYSE:NVS), The patent no. 7030750 titled “antibody molecules t...
IMMP - Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. 7030750 entitled “Antibody molecules to LAG-3 and uses thereof” by the J...

IMMP - Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO's Breast Cancer Congress 2022

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data from its Phase IIb AIPAC trial at ESMO’s Breast Cancer Congress...

IMMP - Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer

SYDNEY, AUSTRALIA, March 10, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical de...
IMMP - Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO's European Lung Cancer Congress 2022

SYDNEY, AUSTRALIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data is scheduled to be presented at ESMO’s European Lung Cancer Congress (ELCC) 2022 which w...

IMMP - Immutep granted Australian patent related to lead product candidate

Immutep (NASDAQ:IMMP) announced on Friday that the Australian Patent Office awarded the company a new patent covering the therapeutic combinations of its lead immunotherapy candidate eftilagimod alpha and a PD-1 pathway inhibitor. Also called efti or IMP32, eftilagimod alpha is a LAG-3 fusion...

IMMP - Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor

SYDNEY, AUSTRALIA, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce ...
IMMP - Immutep to Present at February Investor Conferences

SYDNEY, AUSTRALIA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced today th...

IMMP - Immutep Advances IMP761 Manufacturing

SYDNEY, AUSTRALIA, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce...

IMMP - Immutep in pact with Northway Biotech to manufacture IMP761

Immutep (NASDAQ:IMMP) has signed a Manufacturing Service Agreement (MSA) with Northway Biotech to manufacture IMP761 ahead of clinical testing. Under the agreement, Northway has already started developing a GMP-compliant manufacturing process of IMP761 and will manufacture the drug in large s...
Previous 10 Next 10